Company Overview and News
Elpro International has agreed to sell approximately 1.33 per cent shareholding in PNB MetLife India Insurance Company for a total consideration of ₹134.22 crore. The decision is subject to satisfaction of certain conditions, including approval from the Insurance Regulatory and Development Authority of India and the Competition Commission of India. Elpro International has been holding 12.75 per cent stake in PNB MetLife Insurance since 2003.
504000 ELPROINTL 512068 DECNGOLD
The rights issue of Elpro International will open on Wednesday and close on April 11. It plans to raise up to ₹100 crore through the rights issue by offering 3.11 crore shares at ₹32.10 a share. The entitlement ratio is nine equity shares for every 40 held by existing shareholders in the company as on February 9. Meanwhile, exchange disclosures reveal that its promoters have been increasing their stakes in the firm through creeping acquisitions in the last few days.
504000 ELPROINTL 532693 PUNJLLOYD
Here are some of the top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. Keep an eye on Cipla, Elpro International, Gujarat State Petroleum Corporation (GSPL) and Binani Industries.
504000 ELPROINTL GUJGAS BINANIIND 539336 500059
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...